CD20抗原表达在儿童B系急性淋巴细胞白血病中的相关性
该研究分析了224例初治儿童B系急性淋巴细胞白血病(B-ALL)患者中CD20表达与临床实验室参数及生存特征的关系。50%患者有CD20表达;CD20+组较CD20-组复发更多(16% vs 29%,p=0.034)、无复发生存更差(79% vs 66%,p=0.025),但总生存无差异(75% vs 69%,p=0.126);CD20表达是无复发生存差的独立预测因素(HR 1.860,95%CI 1.008-3.432,p=0.047)。
要点
- CD20+ B-ALL患者复发率高于CD20-患者(16% vs 29%,p=0.034)。
- CD20+ B-ALL患者无复发生存低于CD20-患者(79% vs 66%,p=0.025)。
- CD20表达是无复发生存差的独立预测因素(HR 1.860,95%CI 1.008-3.432,p=0.047)。
核心结论
- CD20表达与儿童B-ALL患者较高的复发率和较差的无复发生存相关,且为无复发生存差的独立预测因素,但与总生存无差异。
- 对于诱导结束时微小残留病(EOI-MRD)阳性的CD20- B-ALL患者,可考虑使用利妥昔单抗,因其残留原始细胞CD20表达有量和质的增加。
研究设计与样本
- 研究分析了224例初治儿童B-ALL患者的临床实验室参数及与CD20表达相关的生存特征。
主要发现
- 50%患者有CD20表达(CD20+ B-ALL)。
- CD20表达与临床和实验室表现及诱导结束时可测量残留病(EOI-MRD)状态无差异。
- CD20+ B-ALL患者较CD20-患者复发更多(16% vs 29%,p=0.034),无复发生存更差(79% vs 66%,p=0.025),但总生存无差异(75% vs 69%,p=0.126)。
- CD20表达是无复发生存差的独立预测因素(HR 1.860,95%CI 1.008-3.432,p=0.047),类似于高危NCI状态和EOI-MRD阳性。
- CD20- B-ALL患者EOI残留原始细胞中CD20表达较基线显著增加(5% vs 13%,p=0.001);CD20+和CD20-患者的EOI残留原始细胞标准化CD20表达强度(nCD20)均增加三倍,CD20- B-ALL患者的强度达到CD20+ B-ALL患者治疗前的nCD20(4.9 vs 3.6,p=0.666)。
关键数值与推荐
- CD20+ B-ALL患者复发率16% vs CD20- B-ALL患者29%(p=0.034)。
- CD20+ B-ALL患者无复发生存79% vs CD20- B-ALL患者66%(p=0.025)。
- CD20+ B-ALL患者总生存75% vs CD20- B-ALL患者69%(p=0.126)。
- CD20表达预测无复发生存差的HR为1.860(95%CI 1.008-3.432,p=0.047)。
- CD20- B-ALL患者EOI残留原始细胞CD20表达较基线5% vs 13%(p=0.001)。
临床怎么用
- 对于EOI-MRD阳性的CD20- B-ALL患者,可考虑使用利妥昔单抗,因其残留原始细胞CD20表达有量和质的增加。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Literature regarding prognostic relevance of CD20 antigen expression among paediatric B-lineage acute lymphoblastic leukaemia (B-ALL) patients is sparse and contradictory. We analysed clinical laboratory parameters and survival characteristics pertinent to CD20 expression among 224 treatment-naïve paediatric B-ALL patients. 50% patients had CD20 expression (CD20+ B-ALL). There was no difference in the clinical & laboratory presentation and end of induction measurable residual disease (EOI-MRD) status according to CD20 expression. As compared to CD20- B-ALL patients, CD20+ B-ALL patients had two times more relapse (16% vs. 29%, p = 0.034), inferior relapse-free survival (79% vs. 66%, p = 0.025) but no difference in overall survival (75% vs. 69%, p = 0.126). Similar to high-risk NCI status and EOI-MRD positivity, CD20 expression was an independent predictor for inferior relapse-free survival (HR: 1.860, 95% CI: 1.008-3.432, p = 0.047). Compared to baseline, there was a significant increase in CD20-expressing EOI-residual blasts among CD20- B-ALL patients (5% vs. 13%, p = 0.001). EOI residual blasts of both CD20+ and CD20- patients had three times increased normalized CD20 expression intensity (nCD20), with the intensity among CD20- B-ALL patients reaching the pretreatment nCD20 of CD20+ B-ALL patients (4.9 vs. 3.6, p = 0.666). Rituximab can be considered in managing EOI-MRD-positive CD20- B-ALL patients as the residual blasts of these patients have quantitative and qualitative increases in CD20 expression.
引用
- Bommannan K, Arumugam JR, Radhakrishnan V, et al. Relevance of CD20 antigen expression among paediatric patients with B-lineage acute lymphoblastic leukaemia. Br J Haematol. 2024. PMID: 38444113. doi:10.1111/bjh.19370
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。